Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer

Source: Aerpio Pharmaceuticals

Aerpio Pharmaceuticals announced that Michael Rogers has been appointed Chief Financial Officer effective as of November 15, 2017. Mr. Rogers has more than 25 years of experience in the biopharmaceutical industry, serving as Chief Financial Officer (CFO) of five publicly-traded healthcare companies.

He most recently served as CFO at Acorda Therapeutics, a biopharmaceutical company from 2013 until 2016. Prior to Acorda Therapeutics, he was the Executive Vice President and CFO of BG Medicine from 2009 to 2012. From 1999 to 2009, Mr. Rogers was the CFO of Indevus Pharmaceuticals until the company’s sale to Endo Pharmaceuticals. He also served as CFO at Advanced Health Corporation and Autoimmune. Prior to his roles as CFO, Mr. Rogers was an investment banker at Lehman Brothers and PaineWebber, where he focused on life sciences companies. Mr. Rogers received his B.A. from Union College, and an M.B.A. from the Darden School of Business at the University of Virginia. He currently serves as Chairman of the Board of Directors of Keryx Pharmaceuticals and as a member of the Board of Directors for pSivida Corp.

“I’m very excited to join Aerpio and work with the existing management team to develop and commercialize first-in-class products which activate the Tie-2 pathway,” Mr. Rogers said in a company news release. “Aerpio has created significant value through understanding the science behind the Tie-2 pathway. Our leading drug candidate, AKB-9778, represents an important target not only in ophthalmology, but in the pathogenesis of “leaky vasculature” which produces significant morbidity in patients with diabetes and other medical conditions.”

“Mr. Rogers’ strong background in both biotechnology and finance, as well as his numerous relationships within the investment community make him an excellent choice to lead our finance efforts,” stated Dr. Joseph Gardner, President and Founder of Aerpio Pharmaceuticals. “In addition to his financial background, Mr. Rogers adds significant management experience which will be critical as we progress our drug candidates.”

Related Content